Mezzion Pharma Statistics

Total Valuation

Mezzion Pharma has a market cap or net worth of KRW 1.23 trillion. The enterprise value is 1.21 trillion.

Market Cap	1.23T
Enterprise Value	1.21T

Important Dates

The next estimated earnings date is Tuesday, August 12, 2025.

Earnings Date	Aug 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Mezzion Pharma has 30.01 million shares outstanding. The number of shares has increased by 3.15% in one year.

Current Share Class	30.01M
Shares Outstanding	30.01M
Shares Change (YoY)	+3.15%
Shares Change (QoQ)	+0.03%
Owned by Insiders (%)	9.45%
Owned by Institutions (%)	6.04%
Float	21.62M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	146.70
PB Ratio	28.51
P/TBV Ratio	29.62
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-53.10
EV / Sales	144.37
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-57.80

Financial Position

The company has a current ratio of 1.33, with a Debt / Equity ratio of 0.03.

Current Ratio	1.33
Quick Ratio	0.85
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.07
Interest Coverage	-46.51

Financial Efficiency

Return on equity (ROE) is -45.26% and return on invested capital (ROIC) is -16.54%.

Return on Equity (ROE)	-45.26%
Return on Assets (ROA)	-10.84%
Return on Invested Capital (ROIC)	-16.54%
Return on Capital Employed (ROCE)	-30.91%
Revenue Per Employee	442.48M
Profits Per Employee	-1.20B
Employee Count	19
Asset Turnover	0.11
Inventory Turnover	1.19

Taxes

In the past 12 months, Mezzion Pharma has paid 4.81 billion in taxes.

Income Tax	4.81B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +4.32% in the last 52 weeks. The beta is 0.26, so Mezzion Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.26
52-Week Price Change	+4.32%
50-Day Moving Average	38,388.00
200-Day Moving Average	32,563.00
Relative Strength Index (RSI)	58.47
Average Volume (20 Days)	99,332

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Mezzion Pharma had revenue of KRW 8.41 billion and -22.86 billion in losses. Loss per share was -764.29.

Revenue	8.41B
Gross Profit	1.77B
Operating Income	-13.75B
Pretax Income	-18.04B
Net Income	-22.86B
EBITDA	-12.78B
EBIT	-13.75B
Loss Per Share	-764.29

Full Income Statement

Balance Sheet

The company has 21.08 billion in cash and 1.48 billion in debt, giving a net cash position of 19.60 billion or 653.19 per share.

Cash & Cash Equivalents	21.08B
Total Debt	1.48B
Net Cash	19.60B
Net Cash Per Share	653.19
Equity (Book Value)	43.26B
Book Value Per Share	1,441.63
Working Capital	8.64B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -20.72 billion and capital expenditures -279.63 million, giving a free cash flow of -21.00 billion.

Operating Cash Flow	-20.72B
Capital Expenditures	-279.63M
Free Cash Flow	-21.00B
FCF Per Share	-699.79

Full Cash Flow Statement

Margins

Gross margin is 21.10%, with operating and profit margins of -163.57% and -271.89%.

Gross Margin	21.10%
Operating Margin	-163.57%
Pretax Margin	-214.63%
Profit Margin	-271.89%
EBITDA Margin	-152.07%
EBIT Margin	-163.57%
FCF Margin	n/a

Dividends & Yields

Mezzion Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.15%
Shareholder Yield	n/a
Earnings Yield	-1.85%
FCF Yield	-1.70%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on April 5, 2022. It was a forward split with a ratio of 3.

Last Split Date	Apr 5, 2022
Split Type	Forward
Split Ratio	3

Scores

Mezzion Pharma has an Altman Z-Score of 18.3 and a Piotroski F-Score of 2.

Altman Z-Score	18.3
Piotroski F-Score	2